[Biologic effects of high doses per fraction].
Effets biologiques des hautes doses par fraction.
Blood Vessels
/ radiation effects
Cell Cycle
/ radiation effects
Cell Death
Cell Proliferation
Cell Survival
Dose Fractionation, Radiation
Humans
Immunity, Cellular
/ radiation effects
Models, Theoretical
Neoplasms
/ radiotherapy
Oxygen Consumption
Radiation Tolerance
Radiobiology
/ legislation & jurisprudence
Radioimmunotherapy
/ methods
Radiosurgery
/ legislation & jurisprudence
Risk Assessment
Ablative radiotherapy
Hypofractionation
Hypofractionnement
Radiobiologie
Radiobiology
Radiochirurgie
Radiosurgery
Radiothérapie ablative
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
06
06
2019
revised:
18
06
2019
accepted:
19
06
2019
pubmed:
25
2
2020
medline:
14
5
2020
entrez:
25
2
2020
Statut:
ppublish
Résumé
The radiobiological concepts described for conventional doses per fraction (1.8 to 2Gy) seem difficult to translate to high doses per fraction radiobiology. In fact, specific mechanisms are involved during high dose per fraction irradiation, involving vascular microenvironment damage and anti tumor immune response. The "5R's" of "classical" radiobiology (factors influencing the response of healthy or cancer cells to irradiation) seem to play a less important role in case of high doses per fraction. In addition, applicability of the linear quadratic model in this context is debated. It is therefore difficult to obtain reliable equivalent doses, hence the importance of including our patients in clinical trials, especially in case of concomitant systemic treatments. In addition to stereotactic radiotherapy, flash irradiations defined by a dose rate approximately 2000 times faster than "conventional" irradiation can also deliver high doses per fraction, with a much better tolerance for normal tissue without loss of anti tumor efficacy. Finally, availability of robust prospective data is a prerequisite to answer the question of short and long-term risk/benefit ratio of these different irradiation techniques.
Identifiants
pubmed: 32089502
pii: S1278-3218(20)30012-3
doi: 10.1016/j.canrad.2019.06.017
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
153-158Informations de copyright
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.